(a) As used in this article:

(i) 'Current good manufacturing practices' means the quality, safety and manufacturing practice standards employed under this act that are consistent with applicable federal law;

(ii) 'Institutional review board' means a group duly constituted and currently registered in accordance with applicable federal law that provides initial approval and continuing oversight of the stem cell therapies being offered under this act, including adverse event reporting and the approval of a form to be used for informed consent between a physician and patient or the patient's legal representative prior to the use of stem cell therapy;

(iii) 'Investigational drug, biological product or device' means a drug, biological product or device that has successfully completed phase one (1) of a clinical trial but has not yet been approved for general use by the United States food and drug administration and remains under investigation in a clinical trial;

(iv) 'Physician' means a person licensed to practice medicine by the state board of medicine pursuant to title 33, chapter 26 of the Wyoming statutes. 'Physician' shall not include a physician assistant as defined by W.S. 33-26-501(a)(iii);

(v) 'Stem cell therapy' means treatment involving the use of autologous mesenchymal stem cells, including but not limited to the collection, processing, cultural expansion, manufacturing, storage and therapeutic use of stem cells. 'Stem cell therapy' shall not include, whether directly or indirectly, the use of any biological material derived from an abortion;

(vi) 'This act' means W.S. 35-4-1101 through 35-4-1106.